Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research report issued on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Price Performance

The firm has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a one year low of $1.22 and a one year high of $8.45. The company has a quick ratio of 0.52, a current ratio of 0.85 and a debt-to-equity ratio of 0.12.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.